CHANGING THE FUTURE, RIGHT ON TIME

The contract research organisation (CRO) works with clinical trial sponsors to undertake pivotal phase 2 and 3 clinical trials in life changing therapeutic areas. This includes inflammatory bowel diseases, oncology, hematology, infectious disease, multiple sclerosis and rare diseases.

Setting PSI CRO apart from its competitors is its ability to plan and execute complex clinical trials on time. And, as everyone knows. Time equals money.

Describing itself as being “obsessed with timelines” PSI CRO is known for “coming to the rescue when trials fall behind and sponsors have to start from scratch”.

Meeting deadlines and enrollment milestones without failure has enabled PSI CRO to build valuable relationships with biotech sponsors. Around 90% of customers are either repeat or referral.

PSI CRO

PROJECT

DIRECTED BY: JAMIE WAITE

ARTICLE

WRITTEN BY: LAURA

WATLING

PSI CRO’s success has led it to build a global network of offices and research centers in over 50 countries. With 2000 employees across North America, Latin America, Europe, Africa, and Asia Pacific, the CRO is dedicated to providing the same service no matter the location.

In 2022 the business was honoured for the fourth year in a row as one of the Best Places to Work.

PSI CRO (King of Prussia) received the award from the Philadelphia Business Journal for beating 76 companies in the top spot.

“Winning this region is no small feat. King of Prussia is home to several of the top clinical research, healthcare, and biotech companies,” the business shared on its website.

Culture is of top priority to PSI, which follows seven core values:

• Delivering Wow Service

• Being a Teammate

• Practicing Accountability

• Delivering Results

• Excelling in Communication

• Being Excellent & Humble

• Staying Lean

With plans for continued organic growth, these values will enable PSI CRO to continue to offer its world-class dedication to customer service.

In the same year, PSI CRO was also named a 2022 CRO Leadership Award Champion for the fifth year in a row. For 2022 this was in the categories of Compatibility, Quality, and Reliability across two respondent groups (Overall and Small Pharma). Winners in these categories are judged by their customers as having exceeded their expectations.

Stated on its website, PSI CRO’s President, Nick Sinackevich said “Our mission is to be the best CRO in the world as measured by our employees, clients, sites, and vendors. Our continuing success in the CRO Leadership Awards is an important benchmark for this goal and a testament to the tireless work of our teams around the world.” www.psi-cro.com

Most recently, the CRO has published a new report on the future of oncology clinical research: Preparing for the Future of Oncology Clinical Research.

Co-authored by PSI’s Dr. Maxim Kosov, Senior Medical Advisor, Operations, and Dr. Victor Zenzola de Toma, Medical Monitor, the paper provides essential insights for sponsors into the trends with the greatest potential to affect clinical trial design and operationalisation.

Highlighted in the report are general trends in oncology, therapeutic advances in the most challenging indications, and additional research highlights in gastrointestinal, gynecological, and genitourinary cancers as well as pediatric oncology and rare disease.

“Oncology studies face unique challenges due to their expansive geographic footprints, lengthy screening and treatment durations, and massive amounts of clinical data,” said Dr. Kosov on PSI CRO’s website, “As the need for oncology clinical trials persists and grows, PSI CRO is committed to keeping abreast of the latest scientific advances and partnering with the companies and investigators doing the most exciting work across the wide range of oncology diseases”.